At the news
? NEUTRALIMPACT 4/10 CLUSTER filed Aug 12, 2026 at 16:19 ET
Three top executives at Bicara Therapeutics (CEO, President/COO, CFO) executed same-day option exercises and open-market sales on August 10, 2026, totaling $1.15M in sales. This cluster follows the company's Q2 earnings report (net loss $0.82/share, in line with consensus) and the announcement of CEO Claire Mazumdar's planned departure in January 2027. The sales are likely liquidity-driven (option exercise to cover taxes and diversification) rather than a bearish signal, but the timing, one day after earnings and amid a leadership transition, warrants attention.
- CEO Claire Mazumdar sold 10,000 shares for $279,750 on August 10, 2026, following option exercise.
- President/COO Ryan Cohlhepp sold 18,750 shares for $524,533 on August 10, 2026, following option exercise.
- CFO Ivan Hyep sold 12,500 shares for $349,591 on August 10, 2026, following option exercise.
- Total open-market sales by the three executives: $1.15M, representing ~0.07% of BCAX's $1.6B market cap.
Before · The news · First close · A day later · A week later
Replay the market's reaction
Step through every 5 minutes around the news, then see how it compares with similar events.
Subscribe for Full Access